Selected research
Industry Research
Human Immune Globulin Intravenous Industry Research Report 2026
Market perspective
The global Human Immune Globulin Intravenous market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Immune Globulin Intravenous is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Immune Globulin Intravenous is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Immune Globulin Intravenous is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Immune Globulin Intravenous include Takeda, Sichuan Yuanda Shuyang, Shanghai RAAS, Hualan Bio, Octapharma, LFB Group, Kedrion, Grifols and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Immune Globulin Intravenous market in terms of revenue (US$ million) and, where applicable, sales volume (units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Immune Globulin Intravenous Market by Company
Takeda
Sichuan Yuanda Shuyang
Shanghai RAAS
Hualan Bio
Octapharma
LFB Group
Kedrion
Grifols
CSL
CNBG
CBPO
BPL
Biotest
Human Immune Globulin Intravenous Segment by Type
IVIg Liquid
IVIg Powder
Human Immune Globulin Intravenous Segment by Application
Autoimmune Disease
Immunodeficiency
Acute Infection
Human Immune Globulin Intravenous Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immune Globulin Intravenous market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Immune Globulin Intravenous and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immune Globulin Intravenous.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Immune Globulin Intravenous manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Immune Globulin Intravenous by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Immune Globulin Intravenous in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- IVIg Liquid
- IVIg Powder
Applications
- Autoimmune Disease
- Immunodeficiency
- Acute Infection
Companies covered
- Takeda
- Sichuan Yuanda Shuyang
- Shanghai RAAS
- Hualan Bio
- Octapharma
- LFB Group
- Kedrion
- Grifols
- CSL
- CNBG
- CBPO
- BPL
- Biotest
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Immune Globulin Intravenous Market Size (2021-2032)
- 2.2.2 Global Human Immune Globulin Intravenous Sales (2021-2032)
- 2.2.3 Global Human Immune Globulin Intravenous Market Average Price (2021-2032)
- 2.3 Human Immune Globulin Intravenous by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 IVIg Liquid
- 2.3.3 IVIg Powder
- 2.4 Human Immune Globulin Intravenous by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Autoimmune Disease
- 2.4.3 Immunodeficiency
- 2.4.4 Acute Infection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Immune Globulin Intravenous Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Immune Globulin Intravenous Sales (units) of Manufacturers (2021-2026)
- 3.3 Global Human Immune Globulin Intravenous Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Immune Globulin Intravenous Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Immune Globulin Intravenous Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Immune Globulin Intravenous, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Immune Globulin Intravenous, Product Type & Application
- 3.8 Global Manufacturers of Human Immune Globulin Intravenous, Established Date
- 3.9 Global Human Immune Globulin Intravenous Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Human Immune Globulin Intravenous Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Sichuan Yuanda Shuyang
- 4.2.1 Sichuan Yuanda Shuyang Company Information
- 4.2.2 Sichuan Yuanda Shuyang Business Overview
- 4.2.3 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Product Portfolio
- 4.2.5 Sichuan Yuanda Shuyang Recent Developments
- 4.3 Shanghai RAAS
- 4.3.1 Shanghai RAAS Company Information
- 4.3.2 Shanghai RAAS Business Overview
- 4.3.3 Shanghai RAAS Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai RAAS Human Immune Globulin Intravenous Product Portfolio
- 4.3.5 Shanghai RAAS Recent Developments
- 4.4 Hualan Bio
- 4.4.1 Hualan Bio Company Information
- 4.4.2 Hualan Bio Business Overview
- 4.4.3 Hualan Bio Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hualan Bio Human Immune Globulin Intravenous Product Portfolio
- 4.4.5 Hualan Bio Recent Developments
- 4.5 Octapharma
- 4.5.1 Octapharma Company Information
- 4.5.2 Octapharma Business Overview
- 4.5.3 Octapharma Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Octapharma Human Immune Globulin Intravenous Product Portfolio
- 4.5.5 Octapharma Recent Developments
- 4.6 LFB Group
- 4.6.1 LFB Group Company Information
- 4.6.2 LFB Group Business Overview
- 4.6.3 LFB Group Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 LFB Group Human Immune Globulin Intravenous Product Portfolio
- 4.6.5 LFB Group Recent Developments
- 4.7 Kedrion
- 4.7.1 Kedrion Company Information
- 4.7.2 Kedrion Business Overview
- 4.7.3 Kedrion Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Kedrion Human Immune Globulin Intravenous Product Portfolio
- 4.7.5 Kedrion Recent Developments
- 4.8 Grifols
- 4.8.1 Grifols Company Information
- 4.8.2 Grifols Business Overview
- 4.8.3 Grifols Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Grifols Human Immune Globulin Intravenous Product Portfolio
- 4.8.5 Grifols Recent Developments
- 4.9 CSL
- 4.9.1 CSL Company Information
- 4.9.2 CSL Business Overview
- 4.9.3 CSL Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CSL Human Immune Globulin Intravenous Product Portfolio
- 4.9.5 CSL Recent Developments
- 4.10 CNBG
- 4.10.1 CNBG Company Information
- 4.10.2 CNBG Business Overview
- 4.10.3 CNBG Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CNBG Human Immune Globulin Intravenous Product Portfolio
- 4.10.5 CNBG Recent Developments
- 4.11 CBPO
- 4.11.1 CBPO Company Information
- 4.11.2 CBPO Business Overview
- 4.11.3 CBPO Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 CBPO Human Immune Globulin Intravenous Product Portfolio
- 4.11.5 CBPO Recent Developments
- 4.12 BPL
- 4.12.1 BPL Company Information
- 4.12.2 BPL Business Overview
- 4.12.3 BPL Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 BPL Human Immune Globulin Intravenous Product Portfolio
- 4.12.5 BPL Recent Developments
- 4.13 Biotest
- 4.13.1 Biotest Company Information
- 4.13.2 Biotest Business Overview
- 4.13.3 Biotest Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Biotest Human Immune Globulin Intravenous Product Portfolio
- 4.13.5 Biotest Recent Developments
5 Global Human Immune Globulin Intravenous Market Scenario by Region
- 5.1 Global Human Immune Globulin Intravenous Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Immune Globulin Intravenous Sales by Region: 2021-2032
- 5.2.1 Global Human Immune Globulin Intravenous Sales by Region: 2021-2026
- 5.2.2 Global Human Immune Globulin Intravenous Sales by Region: 2027-2032
- 5.3 Global Human Immune Globulin Intravenous Revenue by Region: 2021-2032
- 5.3.1 Global Human Immune Globulin Intravenous Revenue by Region: 2021-2026
- 5.3.2 Global Human Immune Globulin Intravenous Revenue by Region: 2027-2032
- 5.4 North America Human Immune Globulin Intravenous Market Facts & Figures by Country
- 5.4.1 North America Human Immune Globulin Intravenous Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Immune Globulin Intravenous Sales by Country (2021-2032)
- 5.4.3 North America Human Immune Globulin Intravenous Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Human Immune Globulin Intravenous Market Facts & Figures by Country
- 5.5.1 Europe Human Immune Globulin Intravenous Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Immune Globulin Intravenous Sales by Country (2021-2032)
- 5.5.3 Europe Human Immune Globulin Intravenous Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Human Immune Globulin Intravenous Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Immune Globulin Intravenous Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Immune Globulin Intravenous Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Immune Globulin Intravenous Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Immune Globulin Intravenous Market Facts & Figures by Country
- 5.7.1 South America Human Immune Globulin Intravenous Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Immune Globulin Intravenous Sales by Country (2021-2032)
- 5.7.3 South America Human Immune Globulin Intravenous Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Human Immune Globulin Intravenous Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Immune Globulin Intravenous Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Immune Globulin Intravenous Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Immune Globulin Intravenous Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Human Immune Globulin Intravenous Sales by Type (2021-2032)
- 6.1.1 Global Human Immune Globulin Intravenous Sales by Type (2021-2032) & (units)
- 6.1.2 Global Human Immune Globulin Intravenous Sales Market Share by Type (2021-2032)
- 6.2 Global Human Immune Globulin Intravenous Revenue by Type (2021-2032)
- 6.2.1 Global Human Immune Globulin Intravenous Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Immune Globulin Intravenous Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Immune Globulin Intravenous Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Immune Globulin Intravenous Sales by Application (2021-2032)
- 7.1.1 Global Human Immune Globulin Intravenous Sales by Application (2021-2032) & (units)
- 7.1.2 Global Human Immune Globulin Intravenous Sales Market Share by Application (2021-2032)
- 7.2 Global Human Immune Globulin Intravenous Revenue by Application (2021-2032)
- 7.2.1 Global Human Immune Globulin Intravenous Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Immune Globulin Intravenous Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Immune Globulin Intravenous Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Immune Globulin Intravenous Value Chain Analysis
- 8.1.1 Human Immune Globulin Intravenous Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Immune Globulin Intravenous Production Mode & Process
- 8.2 Human Immune Globulin Intravenous Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Immune Globulin Intravenous Distributors
- 8.2.3 Human Immune Globulin Intravenous Customers
9 Global Human Immune Globulin Intravenous Analyzing Market Dynamics
- 9.1 Human Immune Globulin Intravenous Industry Trends
- 9.2 Human Immune Globulin Intravenous Industry Drivers
- 9.3 Human Immune Globulin Intravenous Industry Opportunities and Challenges
- 9.4 Human Immune Globulin Intravenous Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst